Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
17.42
-0.59 (-3.28%)
Apr 29, 2026, 2:09 PM EDT - Market open
Zenas BioPharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -377.74 | -156.99 | -37.12 | -119.28 |
| Depreciation & Amortization | 0.06 | 0.14 | 0.11 | 0.08 |
| Loss (Gain) From Sale of Assets | 0.11 | - | - | - |
| Asset Writedown & Restructuring Costs | 171.67 | - | 10 | 1 |
| Loss (Gain) From Sale of Investments | -1.93 | -0.6 | - | - |
| Stock-Based Compensation | 26.35 | 10.82 | 3.5 | 0.74 |
| Other Operating Activities | 8.2 | 1.53 | 1.03 | 43.85 |
| Change in Accounts Payable | -10.04 | 11.74 | -0.42 | 1.09 |
| Change in Other Net Operating Assets | 10.99 | 13.69 | -7.62 | 6.88 |
| Operating Cash Flow | -172.33 | -119.67 | -30.53 | -65.65 |
| Capital Expenditures | -0.02 | -0.13 | -0.02 | -0.2 |
| Sale (Purchase) of Intangibles | -35 | - | - | -2 |
| Investment in Securities | -216.87 | -30.42 | - | - |
| Investing Cash Flow | -251.89 | -30.55 | -0.02 | -2.2 |
| Long-Term Debt Issued | - | - | 20 | - |
| Net Debt Issued (Repaid) | - | - | 20 | - |
| Issuance of Common Stock | 152.95 | 240.91 | 0.12 | - |
| Other Financing Activities | 62.34 | -6.33 | - | - |
| Financing Cash Flow | 215.28 | 412.96 | 20.12 | 59.39 |
| Foreign Exchange Rate Adjustments | -0.25 | 0.16 | 0.08 | -0.04 |
| Net Cash Flow | -209.19 | 262.89 | -10.35 | -8.5 |
| Free Cash Flow | -172.35 | -119.81 | -30.55 | -65.85 |
| Free Cash Flow Margin | -1723.51% | -2396.10% | -61.09% | - |
| Free Cash Flow Per Share | -3.85 | -9.08 | -19.95 | -44.13 |
| Levered Free Cash Flow | -143.11 | -60.01 | -17.64 | - |
| Unlevered Free Cash Flow | -138.53 | -60.01 | -17.64 | - |
| Change in Working Capital | 0.95 | 25.43 | -8.04 | 7.97 |
Source: S&P Capital IQ. Standard template.
Financial Sources.